Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report.
Infect Disord Drug Targets
; 21(7): e160921188928, 2021.
Article
in English
| MEDLINE | ID: covidwho-969257
ABSTRACT
BACKGROUND:
Since December 2019, there has been an increasing number of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world. As of March 2020, the World Health Organization declared a global pandemic. CASE PRESENTATION To our best knowledge, this is the first report of a patient with SARS-CoV-2 infection presenting with constrictive pericarditis, possibly from the COVID infection. She was presented after a week of fever, persistent dry cough, and diarrhea. She received a single dose of hydroxychloroquine 400 mg, Oseltamivir 75 mg every 12 hours, lopinavir/ritonavir (Kaletra) 400/100 mg every 12 hours, and levofloxacin 750 mg daily. After 24 hours, she was immediately transferred to the Intensive Care Unit (ICU) because of dyspnea and progressive respiratory failure with a drop of the O2 saturation to 70%.CONCLUSION:
After a week of progress, her respiratory condition deteriorated again. She was re-admitted to the ICU and she expired. She died due to constrictive pericarditis, most probably caused by SARS-CoV-2.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pericarditis, Constrictive
/
COVID-19
Type of study:
Case report
/
Diagnostic study
Topics:
Long Covid
/
Vaccines
Limits:
Female
/
Humans
Language:
English
Journal:
Infect Disord Drug Targets
Journal subject:
Communicable Diseases
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
1871526520666201209145001
Similar
MEDLINE
...
LILACS
LIS